The option of combining XPO1 inhibitors with apoptotic inhibitors is one of the options attempted in clinical trials to induce complete/partial remissions in six of 14 patients with refractory acute myeloid leukemia who had received a median of three prior therapies (ClinicalTrials.gov: NCT02530476) [102]. The gene discussed is XPO1; the disease is acute myeloid leukemia.